经皮与经胸介入封堵治疗婴儿大型动脉导管未闭

doi:10.6040/j.issn.1671-7554.0.2024.0439

摘要/Abstract

摘要： 目的鉴于婴儿大型动脉导管未闭(patent ductus arteriosus, PDA)的介入治疗充满挑战性,主要原因是婴儿外周血管细,组织稚嫩,而所需封堵器大、输送鞘粗,造成经皮封堵的难度和风险增大。本文旨在探讨经胸与经皮介入封堵婴儿大型PDA的临床疗效。方法回顾性分析145例婴儿期大型PDA患者(PDA直径≥4 mm)临床资料,收集患者的PDA直径、左室舒张末期内径、手术相关数据等指标,根据介入途径的不同,将患儿分为DSA引导下经皮组(95例)和食管超声引导下经胸组(50例)。观察两组患儿的手术疗效。结果两组患儿均取得良好的手术成功率,7~12月龄的两组患儿中,经胸组肺动脉侧缺损平均直径(5.80±1.29)mm(范围4.00~10.00 mm);主动脉侧缺损平均直径(8.14±2.16)mm(范围5.20~15.00 mm),封堵器大小为(8.12±1.65)mm(范围6.00~12.00 mm);经皮组肺动脉侧缺损平均直径(5.14±0.94)mm(范围4.00~9.50 mm);主动脉侧缺损平均直径(6.66±1.25)mm(范围4.00~12.70 mm),封堵器大小为(7.83±1.93)mm(范围6.00~10.00 mm)。以上数据以及两组患者的术后的肺动脉收缩压(pulmonary artery systolic pressure, PASP)均较术前有不同程度的下降(P<0.05)。0~6月龄的两组患儿中,经胸组肺动脉侧缺损平均直径(5.14±1.51)mm(范围4.00~10.00 mm)、主动脉侧缺损平均直径(6.68±1.80)mm(范围4.00~10.00 mm);经皮组肺动脉侧缺损平均直径(5.11±1.24)mm(范围4.00~8.40 mm),主动脉侧缺损平均直径(5.92±0.63)mm(范围5.00~7.00 mm);两组的封堵器大小分别为(7.63±1.67)mm(范围6.00~12.00 mm)和(6.83±1.34)mm(范围6.00~10.00 mm),数据差异无统计学意义。随访结果显示,并未有封堵器脱落、心律失常及残余分流等并发症发生。结论经胸及经皮微创封堵婴儿期大型PDA均是安全有效的治疗方式,对于体质量低、低月龄患儿,若外周血管纤细、穿刺及置管困难的,可采用经胸微创封堵的手术路径。

关键词: 动脉导管未闭, 经胸,经皮封堵, 先天性心脏病

Abstract: Objective To evaluate the clinical efficacy of minimally invasive perpulmonary and percutaneous closure of the patent ductus arteriosus(PDA)in infants. Methods A retrospective analysis was performed on 145 infants diagnosed with a large PDA≥4.0 mm in diameter. Data on PDA size, left ventricular end-diastolic diameter and operation-related parameters were collected for each patient. Based on the different interventional approaches, the infants were divided into two groups: the DSA-guided percutaneous closure group(n=95)and the Echo-guided perpulmonary closure group(n=50). The clinical efficacy of both groups was evaluated. Results Both groups achieved a high success rate of 100% in the Echo-guided perpulmonary closure group and 100% in the percutaneous approach. In the DSA-guided perpulmonary closure group for the patients aged from 7 to 12 months, the mean minimum diameter of PDA at the pulmonary end was(5.80±1.29)mm(range, 4.00-10.00 mm), the mean maximum diameter of PDA at the aortic end was(8.14±2.16)mm(range, 5.20-15.00 mm), and the size of the implanted device was(8.12±1.65)mm(range, 6.00-12.00 mm). Similarly, in the DSA-guided percutaneous closure group, the mean minimum and maximum diameters of PDA were(5.14±0.94)mm(range, 4.00-9.50 mm)and(6.66±1.25)mm(range, 4.00-12.70 mm), respectively. The implanted device size was(7.83±1.93)mm(range, 6.00-10.00 mm). The above data and the postoperative pulmonary artery systolic pressure(PASP)of both groups were lower than before surgery(P<0.05). In the Echo-guided perpulmonary closure group for the patients aged from 0 to 6 months, the mean minimum diameter of PDA at the pulmonary end was(5.14±1.51)mm(range, 4.00-10.00 mm), and the mean maximum diameter of PDA at the aortic end was(6.68±1.80)mm(range, 4.00-10.00 mm). Similarly, in the DSA-guided percutaneous closure group, the mean minimum and maximum diameters of PDA were(5.11±1.24)mm(range, 4.00-8.40 mm)and(5.92±0.63)mm(range, 5.00-7.00 mm), respectively. The implant device size was(7.63±1.67)mm(range, 6.00-12.00 mm)and(6.83±1.34)mm(range, 6.00-10.00 mm)in the two groups, respectively; there were no statistical differences between the two groups. The follow-up results showed that there were no complications such as device dislodgement, arrhythmia, or residual shunt. Conclusion Both the perpulmonary and percutaneous approaches for the closure of large PDA devices in infants are safe and effective. The perpulmonary approach is particularly suitable for low-birth-weight and preterm infants, especially in cases with limited accessibility and peripheral vascular challenges.

Key words: Patent ductus arteriosus, Perpulmonary, percutaneous closure, Congenital heart disease

中图分类号:

R654.2

孔中政,高植,孙士彬,李红昕. 经皮与经胸介入封堵治疗婴儿大型动脉导管未闭[J]. 山东大学学报 (医学版), 2024, 62(11): 32-39.

KONG Zhongzheng, GAO Zhi, SUN Shibin, LI Hongxin. Clinical efficacy of percutaneous and transthoracic interventional occlusion in the treatment of large patent ductus arteriosus in infants[J]. Journal of Shandong University (Health Sciences), 2024, 62(11): 32-39.

参考文献

[1] Zhou ZM, Gu YR, Zheng H, et al. Transcatheter closure of patent ductus arteriosus via different approaches[J]. Front Cardiovasc Med, 2022, 8: 797905. doi:10.3389/fcvm.2021.797905.
[2] Warnock A, Szatkowski L, Lakshmanan A, et al. Surgical management of patent ductus arteriosus in pre-term infants-a British paediatric surveillance study[J]. BMC Pediatr, 2021, 21(1): 270. doi:10.1186/s12887-021-02734-9.
[3] Suciu H, Harpa MM, Moraru L, et al. Surgical treatment for patent ductus arteriosus in adult patients: a single center experience[J]. Rev Roum De Morphol Embryol, 2022, 63(4): 633-638.
[4] 肖丽苗, 刘金桥, 陈丽丽, 等. 经食管超声心动图独立引导经股静脉途径封堵治疗儿童动脉导管未闭[J]. 中国医学影像技术, 2023, 39(6): 839-842. XIAO Limiao, LIU Jinqiao, CHEN Lili, et al. Transesophageal echocardiography alone for guiding transcatheter closure of patent ductus arteriosus via femoral vein in children[J]. Chinese Journal of Medical Imaging Technology, 2023, 39(6): 839-842.
[5] 叶赞凯, 李志强, 伊寒露, 等. 单纯超声心动图引导下的经皮及经胸封堵儿童动脉导管未闭的对比研究[J]. 中国循环杂志, 2019, 34(10): 990-993. YE Zankai, LI Zhiqiang, YI Hanlu, et al. Comparative study of the transthoracic and percutaneous device closure treatments for childhood patent ductus arteriosus guided by echocardiography[J]. Chinese Circulation Journal, 2019, 34(10): 990-993.
[6] 王祥, 陈智, 向金星, 等. 国产双盘无膜双腰封堵器介入治疗低体重婴儿粗长管型动脉导管未闭[J]. 中国介入心脏病学杂志, 2022, 30(6): 426-429. WANG Xiang, CHEN Zhi, XIANG Jinxing, et al. Interventional treatment of low weight patent ductus arteriosus with domestic non-membrane double waist occluder[J]. Chinese Journal of Interventional Cardiology, 2022, 30(6): 426-429.
[7] Barry OM, Gudausky TM, Balzer DT, et al. Safety and short-term outcomes for Infants<2.5 kg undergoing PDA device closure: a C3PO registry study[J]. Pediatr Cardiol, 2023, 44(6): 1406-1413.
[8] Antunes Sarmento J, Correia-Costa A, Gonçalves E, et al. Percutaneous patent ductus arteriosus closure: twelve years of experience[J]. Rev Port Cardiol, 2021, 40(8): 561-568.
[9] Jain A, Shah PS. Diagnosis, evaluation, and management of patent ductus arteriosus in preterm neonates[J]. JAMA Pediatr, 2015, 169(9): 863-872.
[10] Backes CH, Cheatham SL, Deyo GM, et al. Percutaneous patent ductus arteriosus(PDA)closure in very preterm infants: feasibility and complications[J]. J Am Heart Assoc, 2016, 5(2): e002923. doi:10.1161/JAHA.115.002923.
[11] Lam JY, Lopushinsky SR, Ma IWY, et al. Treatment options for pediatric patent ductus arteriosus: systematic review and meta-analysis[J]. Chest, 2015, 148(3): 784-793.
[12] Fraisse A, Bautista-Rodriguez C, Burmester M, et al. Transcatheter closure of patent ductus arteriosus in infants with weight under 1,500 grams[J]. Front Pediatr, 2020, 8: 558256. doi:10.3389/fped.2020.558256.
[13] Salam A, Bautista-Rodriguez C, Karsenty C, et al. Transcatheter closure of tubularpatent ductus arteriosus using muscular ventricular septal defect devices in infants and small children with congestive heart failure[J]. Arch Cardiovasc Dis, 2022, 115(3): 134-141.
[14] Zhou ZM, Gu YR, Zheng H, et al. Interventional occlusion of large patent ductus arteriosus in adults with severe pulmonary hypertension[J]. J Clin Med, 2023, 12(1): 354.
[15] Zahn EM, Peck D, Phillips A, et al. Transcatheter closure of patent ductus arteriosus in extremely premature newborns: early results and midterm follow-up[J]. JACC Cardiovasc Interv, 2016, 9(23): 2429-2437.
[16] Lai KC, Richardson T, Berman D, et al. Current trends in invasive closure of patent ductus arteriosus in very low birth weight infants in United States childrens hospitals, 2016-2021[J]. J Pediatr, 2023, 263: 113712. doi:10.1016/j.jpeds.2023.113712.
[17] Tolia VN, Powers GC, Kelleher AS, et al. Low rate of spontaneous closure in premature infants discharged with a patent ductus arteriosus: a multicenter prospective study[J]. J Pediatr, 2022, 240: 31-36. doi:10.1016/j.jpeds.2021.07.035.
[18] 周泽明,王宏茂,郑宏,等.不同介入封堵入路治疗儿童(≤7岁)动脉导管未闭的临床疗效分析[J].中国胸心血管外科临床杂志, 2023, 30(5): 699-703. ZHOU Zeming, WANG Hongmao, ZHENG Hong, et al. Clinical efficacy analysis of different interventional approaches for patent ductus arteriosus in children(≤7 years)[J]. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2023, 30(5): 699-703.
[19] Noori S, McCoy M, Friedlich P, et al. Failure of ductus arteriosus closure is associated with increased mortality in preterm infants[J]. Pediatrics, 2009, 123(1): 138-144.
[20] Hongxin HX, Wenbin WB, Zhu M, et al. New minimally invasive technique of perpulmonary device closure of patent ductus arteriosus through a parasternal approach[J]. Ann Thorac Surg, 2012, 93(3): 862-868.
[21] 李红昕, 訾捷, 郭文彬, 等. 经胸骨旁途径微创动脉导管未闭封堵术[J]. 中华胸心血管外科杂志, 2010, 26(6): 422-423.
[22] Sun SB, Changwe GJ, Farhaj Z, et al. Perpulmonary device dlosure of patent ductus arteriosus with minimum diameter more than 4 mm in infants[J]. Congenit Heart Dis, 2022, 17(4): 437-445.
[23] Rong X, Ye QF, Wang QY, et al. Post-interventional evaluation and follow-up in children with patent ductus arteriosus complicated with moderate to severe pulmonary arterial hypertension: a retrospective study[J]. Front Cardiovasc Med, 2021, 8: 693414. doi:10.3389/fcvm.2021.693414.
[24] Sathanandam S, Gutfinger D, Morray B, et al. Consensus guidelines for the prevention and management of periprocedural complications of transcatheter patent ductus arteriosus closure with the amplatzer piccolo occluder in extremely low birth weight infants[J]. Pediatr Cardiol, 2021, 42(6): 1258-1274.
[25] Markush D, Tsing JC, Gupta S, et al. Fate of the left pulmonary artery and thoracic aorta after transcatheter patent ductus arteriosus closure in low birth weight premature infants[J]. Pediatr Cardiol, 2021, 42(3): 628-636.
[26] 杨晓斐,韩波,姜殿东,等.经导管射频消融术治疗儿童快速性心律失常972例临床分析[J].山东大学学报(医学版), 2023, 61(2): 49-56. YANG Xiaofei, HAN Bo, JIANG Diandong, et al. A clinical analysis of radiofrequency catheter ablation of tachyarrhythmia in 972 children in a single center[J]. Journal of Shandong University(Health Sciences), 2023, 61(2): 49-56.
[27] Uppal L, Rohit MK, Barwad P, et al. Comparison of isolated venous approach with the standard approach in children undergoing patent ductus arteriosus device closure[J]. Egypt Heart J, 2020, 72(1): 65.
[28] Wesselowski S, Saunders AB. Transesophageal echocardiography using a microprobe for determination of transcatheter procedural candidacy, device selection, and procedural monitoring in small dogs with patent ductus arteriosus[J]. J Vet Cardiol, 2024, 52:35-42. doi:10.1016/j.jvc.2024.02.007.
[29] 王锐,张伟,初竹秀,等.经胸右心声学造影联合对比增强经颅多普勒对卵圆孔未闭右向左分流的诊断价值[J].山东大学学报(医学版), 2024, 62(2): 36-41. WANG Rui, ZHANG Wei, CHU Zhuxiu, et al. Diagnostic value of contrast-transthoracic echocardiography plus contrast-enhanced transcranial Doppler for patent foramen ovale-right to left shunt[J]. Journal of Shandong University(Health Sciences), 2024, 62(2): 36-41.
[30] 凌雁, 郭保静, 王志远, 等. X线透视下直接经皮股静脉途径封堵未闭动脉导管的临床研究[J]. 中国循环杂志, 2020, 35(1): 67-71. LING Yan, GUO Baojing, WANG Zhiyuan, et al. Feasibility and safety of percutaneous device occlusion of the patent ductus arteriosus under X-ray without aortography[J]. Chinese Circulation Journal, 2020, 35(1): 67-71.
[31] Baruteau AE, Hascoёt S, Baruteau J, et al. Transcatheter closure of patent ductus arteriosus: past, present and future[J]. Arch Cardiovasc Dis, 2014, 107(2): 122-132.
[32] Eilers LF, Kyle WB, Allen HD, et al. Patent ductus arteriosus[J]. Pediatr Rev, 2021, 42(11): 632-634.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed